Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy

Infection Control and Hospital Epidemiology

Volumn 34, Issue 2, 2013, Pages 127-132

  Wang, Michael S ^a   Evans, Charlesnika T ^b,c   Rodriguez, Tulio ^a   Gerding, Dale N ^a,b   Johnson, Stuart ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; IMMUNOSUPPRESSIVE AGENT; METRONIDAZOLE; VANCOMYCIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKOCYTE COUNT; MALE; MEDICAL RECORD REVIEW; NEUTROPENIA; RESTRICTION MAPPING; SCORING SYSTEM;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CREATININE; FEMALE; HEMATOLOGIC NEOPLASMS; HOSPITALS, TEACHING; HUMANS; LEUKOCYTE COUNT; MALE; MEDICAL AUDIT; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 84872193125     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/669081     Document Type: Article

References (23)

1. McDonald CL, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-2441.
2. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-2449.
3. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366: 1079-1084.
4. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-415.
5. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-1036.
6. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007;45:1543-1549.
7. Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA. Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 2005;26:680-684.
8. Rojas S, Cohen SH, Tang YJ, Wilson J, Inciardi J, Silva J, Jr. Differing epidemiology of Clostridium difficile-associated diarrhea between an oncology ward and a general medicine ward. Infect Control Hosp Epidemiol 1999;20:14-15.
9. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile- associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-1260.
10. Clabots CR, Johnson S, Bettin KM, et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Micro 1993;31:1870-1875.
11. Zar FA, Srinivasa R. Bakkanagari SR, Moorth KM. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-307.
12. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007; 55:495-501.
13. Cohen SH, Gerding DN, Johnson S. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-455.
14. Biller P, Shank B, Lind L. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2006;28:198-201.
15. Husain A, Aptaker L, Spriggs DR, Barakat RR. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 1998;71:104-107.
16. Anand A, Glatt A. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993;17: 109-113.
17. Gifford AH, Kirkland KB. Risk factors for Clostridium difficile- associated diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol Infect Dis 2006;25:751-755.
18. Kamboj M, Khosa P, Kaltsas A, Babady NE, Son C, Sepkowitz KA. Relapse versus reinfection: surveillance of Clostridium difficile infection. Clin Infect Dis 2011;53:1003-1006.
19. Black SR, Weaver KN, Jones RC, et al. Clostridium difficile outbreak strain BI is highly endemic in Chicago area hospitals. Infect Control Hosp Epidemiol 2011;32:897-902.
20. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010;50:194-201.
21. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008;6: 122-174.
22. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012;54: 1053-1063.
23. Fujitani S, George WL, Murthy AR. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 2011;32:220-228.